We are live on ! Find out more
FUL icon

H.B. Fuller

Positive
Neutral
Negative
Sentiment 3-Months
Positive 42.1%
Neutral 55.3%
Negative 2.6%

Positive
Zacks Investment Research
5 days ago
Should Value Investors Buy H. B. Fuller (FUL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy H. B. Fuller (FUL) Stock?
Neutral
Zacks Investment Research
6 days ago
FUL Stock Is Riding Medical, Aerospace and Pricing Trends
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
FUL Stock Is Riding Medical, Aerospace and Pricing Trends
Neutral
Zacks Investment Research
6 days ago
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
Positive
Zacks Investment Research
6 days ago
H.B. Fuller Stock Outlook Hinges on Margins, Mix and M&A
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
H.B. Fuller Stock Outlook Hinges on Margins, Mix and M&A
Neutral
Zacks Investment Research
9 days ago
FUL vs. PPG: Which Stock Is the Better Value Option?
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
FUL vs. PPG: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
15 days ago
H.B. Fuller Q2 Earnings Call Flags Pricing, AMS Ambitions
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
H.B. Fuller Q2 Earnings Call Flags Pricing, AMS Ambitions
Neutral
Seeking Alpha
19 days ago
H.B. Fuller: Overreaction, Or Proof Of Slowdown
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
H.B. Fuller: Overreaction, Or Proof Of Slowdown
Neutral
Seeking Alpha
20 days ago
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
Neutral
Business Wire
20 days ago
Ancora Condemns H.B. Fuller's Decision to Ignore Shareholder Opposition and Proceed with the Reckless Acquisition of Advanced Medical Solutions
CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) today released the below statement regarding H.B. Fuller Company (NYSE: FUL) (“H.B. Fuller” or the “Company”) and Advanced Medical Solutions Group plc (“AMS”). Previously, Ancora issued a letter to H.B. Fuller's Board of Directors (the “Board”) regarding its contemplated acquisition of AMS. Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President.
Ancora Condemns H.B. Fuller's Decision to Ignore Shareholder Opposition and Proceed with the Reckless Acquisition of Advanced Medical Solutions
Negative
Benzinga
20 days ago
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday.
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session